[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/28, WED) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 [ESMO] 루닛, 서밋과 '이보네스시맙' 파트너십 "진짜 의미는?"
[https://www.biospectator.com/news/view/30197](https://www.biospectator.com/news/view/30197)

 라이트팜텍, '소아근시 진행억제' 점안액 “식약처 허가”
[https://www.biospectator.com/news/view/30185](https://www.biospectator.com/news/view/30185)

 [ESMO] 암젠, '임델트라' SCLC서 "전례없는 효능..박수갈채"
[https://www.biospectator.com/news/view/30178](https://www.biospectator.com/news/view/30178)

 [ESMO] 베링거, 'DLL3xCD3 TCE' 병용 SCLC 1b상 "cORR 65%"
[https://www.biospectator.com/news/view/30201](https://www.biospectator.com/news/view/30201)

 쿼드메디슨, '탈모 마이크로니들' 플랫폼 연구성과 발표 
[https://www.biospectator.com/news/view/30223](https://www.biospectator.com/news/view/30223)

 한미약품, 3Q 매출 3774억 "전년比 4.2% 증가"
[https://www.biospectator.com/news/view/30218](https://www.biospectator.com/news/view/30218)

 아티바, 'NK세포' 자가면역 개발중단.."직원 94% 해고”
[https://www.biospectator.com/news/view/30219](https://www.biospectator.com/news/view/30219)

 [ESMO] AZ, 'CLDN18.2 ADC' 위암 3상 “OS 5→10개월, 2배”
[https://www.biospectator.com/news/view/30202](https://www.biospectator.com/news/view/30202)

 인벤테라, 美UCSF와 '나노스캐폴드 ADC' 개발 공동연구
[https://www.biospectator.com/news/view/30225](https://www.biospectator.com/news/view/30225)

 [ESMO] 머크, 'TROP2 ADC' OS·PFS 개선 "첫 글로벌 3상 성공"
[https://www.biospectator.com/news/view/30203](https://www.biospectator.com/news/view/30203)

 삼성바이오에피스, 3Q 매출 4422억·영업이익 1326억 
[https://www.biospectator.com/news/view/30227](https://www.biospectator.com/news/view/30227)

 한올바이오파마, 3Q 매출 399억 "전년比 2,2% 감소"
[https://www.biospectator.com/news/view/30228](https://www.biospectator.com/news/view/30228)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/28, WED) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)